<![CDATA[
<p>[이베스트 제약/바이오 강하나] <br><br><2/22 아침뉴스 업데이트> <br><br>GC녹십자, ‘국소지혈제’ 출혈예방 연구자임상 논문 <br><a href="https://bit.ly/3EoXnSf" target="_blank" class="ke-link">https://bit.ly/3EoXnSf</a><br><br>코렌텍, 작년 매출 639억원…해외 매출 73% 증가 <br><a href="https://bit.ly/3ZdmejY" target="_blank" class="ke-link">https://bit.ly/3ZdmejY</a><br><br>이오플로우, 320억원 규모 "CB 발행 결정" <br><a href="https://bit.ly/3EokoF9" target="_blank" class="ke-link">https://bit.ly/3EokoF9</a><br><br>서범석 루닛 대표 "AI로 질병 진단 넘어 항암제 개발 도울 것" <br><a href="http://bit.ly/3Kpj6gU" target="_blank" class="ke-link">http://bit.ly/3Kpj6gU</a><br><br>액체생검 기술로 담도암 조기진단한다 <br><a href="https://bit.ly/3EvbWno" target="_blank" class="ke-link">https://bit.ly/3EvbWno</a><br><br>올리패스, 비마약성 진통제 'OLP-1002' 일본 특허 취득 <br><a href="https://bit.ly/3XQWCZh" target="_blank" class="ke-link">https://bit.ly/3XQWCZh</a><br><br>붙이면 꿀잠…신신제약 '멜라토닌 패치' 내놓는다 <br><a href="https://bit.ly/3lL4lur" target="_blank" class="ke-link">https://bit.ly/3lL4lur</a><br><br>모더나, ‘mRNA 4가 독감백신’ 3상 중간 “기대이하” <br><a href="https://bit.ly/3EtJh2c" target="_blank" class="ke-link">https://bit.ly/3EtJh2c</a><br><br>獨머크, 아킬리온서 전임상 ‘TAK1 저해제’ 10억弗 L/I <br><a href="https://bit.ly/3xGtI3x" target="_blank" class="ke-link">https://bit.ly/3xGtI3x</a><br><br>키에지, α-만노사이드축적증 "첫 ‘ERT’ 美 승인” <br><a href="https://bit.ly/3xFLOmb" target="_blank" class="ke-link">https://bit.ly/3xFLOmb</a><br><br>헥사곤, 시리즈B 7730만弗..”진균 대사산물 항암제" <br><a href="https://bit.ly/3ShilbL" target="_blank" class="ke-link">https://bit.ly/3ShilbL</a><br><br>'면역관용 세포치료제' 탈라리스, “1/3 인력감축" <br><a href="https://bit.ly/3KypgeR" target="_blank" class="ke-link">https://bit.ly/3KypgeR</a><br><br>‘라게브리오’ 코로나 노출 후 예방효과 “未입증” <br><a href="http://bit.ly/3kcUz45" target="_blank" class="ke-link">http://bit.ly/3kcUz45</a><br><br>美FDA, 아스텔라스 ‘페졸리네탄트’ 심사기간 3개월 연장 <br><a href="http://bit.ly/3lVqQNo" target="_blank" class="ke-link">http://bit.ly/3lVqQNo</a><br><br></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="GC녹십자, ‘국소지혈제’ 출혈예방 연구자임상 논문" data-og-description="GC녹십자(GC Biopharma)는 21일 국소지혈제 ‘그린플라스트큐(Greenplast Q)’의 연구자주도 임상에서 내시경적 점막하박리술(ESD)을 받은 환자를 대상" data-og-host="www.biospectator.com" data-og-source-url="https://bit.ly/3EoXnSf" data-og-url="http://www.biospectator.com/view/news_view.php?varAtcId=18327" data-og-image="https://scrap.kakaocdn.net/dn/bN2NnY/hyRIo18s8t/Hf3uym9zBG5NsMqEkAscNK/img.jpg?width=600&height=304&face=0_0_600_304"><a href="https://bit.ly/3EoXnSf" target="_blank" data-source-url="https://bit.ly/3EoXnSf"><div class="og-image" style="background-image:url(https://scrap.kakaocdn.net/dn/bN2NnY/hyRIo18s8t/Hf3uym9zBG5NsMqEkAscNK/img.jpg?width=600&height=304&face=0_0_600_304)"></div><div class="og-text"><p class="og-title">GC녹십자, ‘국소지혈제’ 출혈예방 연구자임상 논문</p><p class="og-desc">GC녹십자(GC Biopharma)는 21일 국소지혈제 ‘그린플라스트큐(Greenplast Q)’의 연구자주도 임상에서 내시경적 점막하박리술(ESD)을 받은 환자를 대상</p><p class="og-host">www.biospectator.com</p></div></a></div><p> </p><p><span data-ke-size="size14">*** 본 정보는 투자 참고용 자료로서 그 정확성이나 완전성을 보장할 수 없으며, 어떠한 경우에도 법적 책임소재에 대한 증빙자료로 사용될 수 없습니다.</span></p><div class="table-wrap"><table data-ke-type="table" data-ke-align="alignLeft" style="width: 100%; height: 75px;" border="1" data-ke-style="style13"><tbody><tr style="height: 75px;"><td style="width: 756px; height: 75px; text-align: center;"><a href="https://cafe.daum.net/stockwang/As9F/3070" target="_blank" class="ke-link"><span style="color: #ee2323;" data-ke-size="size26"><b>'돈' 잃지 마라! '돈'을 지켜라! 그리고 '돈'을 불려라!</b></span></a></td></tr></tbody></table></div><p> </p>
<!-- -->
]]>
